蚌埠医学院学报
蚌埠醫學院學報
방부의학원학보
ACTA ACADEMIAE MEDICINAE BENGBU
2014年
11期
1508-1511,1514
,共5页
癌,非小细胞肺%生物免疫治疗%树突状细胞%杀伤细胞
癌,非小細胞肺%生物免疫治療%樹突狀細胞%殺傷細胞
암,비소세포폐%생물면역치료%수돌상세포%살상세포
carcinoma,non-small cell lung%biological immune therapy%dendritic cell%killers cell
目的：对树突状细胞( DC)和细胞因子诱导的杀伤细胞( CIK)联合化疗治疗晚期非小细胞肺癌( NSCLC)的相关文献进行Meta分析,了解生物免疫治疗联合化疗治疗晚期NSCLC的临床疗效。方法：检索中文期刊数据库、维普数据库、万方数据库及PubMed、CBM等西文数据库,查找DC-CIK或CIK联合化疗治疗NSCLC的临床研究文献。采用Jadad评分量表对纳入文献进行质量评价,使用Revman 4.2统计软件对临床疗效、生活质量及免疫检测指标( CD3+、CD4+、CD4+/CD8+)进行Meta分析。结果：经筛选后纳入11篇随机对照临床试验文献,质量分析显示纳入文献质量不高。临床获益合并效应比值比( OR)为2.45,95%CI为1.56~3.83；生活质量合并效应量OR为3.17,95%CI为1.82~5.52；治疗后免疫学检测指标CD3+的合并效应量 OR为16.96,95%CI为14.09~17.82；CD4+的合并效应量 OR为6.84,95%CI为6.06~8.63；CD4+/CD8+的合并效应量OR为0.60,95%CI为0.56~0.65。 DC-CIK或CIK联合化疗治疗NSCLC的临床获益率及生活质量明显优于对照组,治疗后免疫功能也优于对照组。结论：DC-CIK或CIK能明显提高晚期NSCLC患者的临床获益率及生活质量,并能提高化疗后患者免疫功能。
目的：對樹突狀細胞( DC)和細胞因子誘導的殺傷細胞( CIK)聯閤化療治療晚期非小細胞肺癌( NSCLC)的相關文獻進行Meta分析,瞭解生物免疫治療聯閤化療治療晚期NSCLC的臨床療效。方法：檢索中文期刊數據庫、維普數據庫、萬方數據庫及PubMed、CBM等西文數據庫,查找DC-CIK或CIK聯閤化療治療NSCLC的臨床研究文獻。採用Jadad評分量錶對納入文獻進行質量評價,使用Revman 4.2統計軟件對臨床療效、生活質量及免疫檢測指標( CD3+、CD4+、CD4+/CD8+)進行Meta分析。結果：經篩選後納入11篇隨機對照臨床試驗文獻,質量分析顯示納入文獻質量不高。臨床穫益閤併效應比值比( OR)為2.45,95%CI為1.56~3.83；生活質量閤併效應量OR為3.17,95%CI為1.82~5.52；治療後免疫學檢測指標CD3+的閤併效應量 OR為16.96,95%CI為14.09~17.82；CD4+的閤併效應量 OR為6.84,95%CI為6.06~8.63；CD4+/CD8+的閤併效應量OR為0.60,95%CI為0.56~0.65。 DC-CIK或CIK聯閤化療治療NSCLC的臨床穫益率及生活質量明顯優于對照組,治療後免疫功能也優于對照組。結論：DC-CIK或CIK能明顯提高晚期NSCLC患者的臨床穫益率及生活質量,併能提高化療後患者免疫功能。
목적：대수돌상세포( DC)화세포인자유도적살상세포( CIK)연합화료치료만기비소세포폐암( NSCLC)적상관문헌진행Meta분석,료해생물면역치료연합화료치료만기NSCLC적림상료효。방법：검색중문기간수거고、유보수거고、만방수거고급PubMed、CBM등서문수거고,사조DC-CIK혹CIK연합화료치료NSCLC적림상연구문헌。채용Jadad평분량표대납입문헌진행질량평개,사용Revman 4.2통계연건대림상료효、생활질량급면역검측지표( CD3+、CD4+、CD4+/CD8+)진행Meta분석。결과：경사선후납입11편수궤대조림상시험문헌,질량분석현시납입문헌질량불고。림상획익합병효응비치비( OR)위2.45,95%CI위1.56~3.83；생활질량합병효응량OR위3.17,95%CI위1.82~5.52；치료후면역학검측지표CD3+적합병효응량 OR위16.96,95%CI위14.09~17.82；CD4+적합병효응량 OR위6.84,95%CI위6.06~8.63；CD4+/CD8+적합병효응량OR위0.60,95%CI위0.56~0.65。 DC-CIK혹CIK연합화료치료NSCLC적림상획익솔급생활질량명현우우대조조,치료후면역공능야우우대조조。결론：DC-CIK혹CIK능명현제고만기NSCLC환자적림상획익솔급생활질량,병능제고화료후환자면역공능。
Objective:To study the clinical efficacy of biological immune therapy of dendritic cell(DC) or cytokine-induced killers cell( CIK) combined with chemotherapy in the treatment of advanced non-small cell lung cancer( NSCLC) by using Meta-analysis and systematic review of the literature. Methods:Randomized controlled trials( RCT) papers were searched in China Academic Journals, China National Knowledge Infrastructure,WeiPu and Wanfang database,PubMed and CBM foreign database. Jadad scale was used to devalue the quality of the included papers;Meta-analysis of the clinical efficacy,the life quality and the immunologic function( CD3 +、CD4 +、CD4 + /CD8 +) was performed with Revman 4. 2 software. Results:Eleven RCT papers were included after screening,and the quality of the papers obtained low Jadad score. Meta-analysis showed that the odds ratio( OR) of the combined clinical benefit rate was 2. 45,95% CI 1. 56 to 3. 83;the OR of the life quality was 3. 17,95%CI 1. 82 to 5. 52. After treatment,the levels of CD3 + in the immunotherapy group increased to 16. 96,95%CI 14. 09 to 17. 82,the levels of CD4 + increased to 6. 84,95%CI 6. 06 to 8. 63 and the levels of CD4 + /CD8 + increased to 0. 60,95%CI 0. 56 to 0. 65. The clinical benefit rate and the immunologic function rate of the DC-CIK therapy or CIK combined with chemotherapy were superior to those of the control in the treatment of NSCLC. Conclusions:Biological immune therapy of DC-CIK or CIK combined with chemotherapy can help to improve the clinical benefit rate,the life quality and immunologic function of the patients with advanced NSCLC.
